Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Xenon Pharmaceuticals Inc. (XENE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in late November to mid-December Continued progress across all XEN1101 Phase 3 epilepsy programs including in X-TOLE2 and X-TOLE3 clinical trials in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures Xenon to host XEN1101 MDD Webinar in mid-September to discuss Kv modulation in MDD, the X-NOVA clinical trial and the broader MDD landscape Conference call at 4:30 pm ET today"
08/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover"
05/09/2023 8-K Quarterly results
Docs: "Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update XEN1101 Phase 3 epilepsy program continues to make significant progress across all ongoing clinical trials including the recent initiation of X-TOLE3 in addition to the ongoing X-TOLE2 and X-ACKT Phase 3 clinical trials Anticipate last patient to be screened next month in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in fourth quarter Conference call at 4:30 pm ET today"
03/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "RE: Xenon Pharmaceuticals Inc. Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders: Date of meeting: June 1, 2023 Record date for notice: April 4, 2023 Record date for voting: April 4, 2023 Beneficial ownership determination date: April 4, 2023 Securities entitled to notice: Common Shares Securities entitled to vote: Common Shares Issuer mailing directly to non objecting beneficial owners: No Issuer will pay for objecting beneficial owner material distribution: Yes Issuer using notice-and-access for registered investors: No Issuer using notice-and-access for non-registered investors: No Notice-and-access stratification criteria: N/A Yours very truly, /s/ John Lundberg John ..."
03/01/2023 8-K Quarterly results
Docs: "Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update XEN1101 Phase 3 epilepsy program continues to advance in focal onset seizures and primary generalized tonic clonic seizures Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder expected in third quarter Conference call at 4:30 pm ET today"
11/08/2022 8-K Quarterly results
11/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
08/09/2022 8-K Quarterly results
Docs: "Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Xenon remains on track to initiate the XEN1101 Phase 3 program within second half of this year"
06/23/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/22/2022 8-K Unregistered Sales of Equity Securities  Interactive Data
03/10/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SEDAR filing submitted March 10, 2022"
03/01/2022 8-K Quarterly results
03/01/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update Conference Call at 4:30 pm ET Today"
01/12/2022 8-K Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Share Purchase Agreement, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc",
"Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone"
12/01/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Lease Agreement, by and between the Company and Redstone Enterprises Ltd"
11/10/2021 8-K Quarterly results
Docs: "Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update XEN1101 X-TOLE Presentations Scheduled at AES 2021 with Planning Underway for Phase 3 Initiation in 2022 Conference Call at 4:30 pm ET Today"
10/06/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, among Xenon Pharmaceuticals Inc., Jefferies LLC, SVB Leerink LLC, and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein",
"Form of Pre-Funded Warrant",
"Opinion of Blake, Cassels & Graydon LLP"
10/04/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of"
09/08/2021 8-K Quarterly results
08/23/2021 8-K Quarterly results
08/11/2021 8-K Quarterly results
06/03/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
03/12/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
01/14/2021 8-K/A Quarterly results
01/14/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update Experienced Biotech Executive, Patrick Machado, Joins Xenon’s Board of Directors Conference Call at 4:30 pm ET Today"
08/17/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy